Home|Journals|Articles by Year|Audio Abstracts
 

Original Article



Synthesis, preliminary anticonvulsant and toxicity screening of substituted {1-[4-Methyl-2-substitutedphenyl-2,5-dihydro-1,5- benzothiazepin-3-yl]-ethylidene}-hydrazine

Vikash Kumar Chaudhri, Devender Pathak, Zeashan Hussain.




Abstract
Cited by 4 Articles

1,5-benzothiazepine moiety is a very important pharmacophore bioactive compound that exhibits different biological activities. The basic constituent of benzodiazepine nucleus is diltiazem. 1,5-benzothiazepine nucleus shows different potential biological activities in various field. Our research mainly focuses on synthesis of new substituted benzodiazepine nucleus which retained anticonvulsant biological activities with less toxic effect. We synthesized successfully various substituted {1-[4-Methyl-2-substitutedphenyl-2,5-dihydro-1,5-benzothiazepin-3-yl]-ethylidene}- hydrazine (6a–6j) and chemical structures confirmed by chromatographic, electro analytical, and physiochemical methods. The preliminary screening of novel synthesized compounds anticonvulsant activity by maximal electroshock model. Based on anticonvulsant screening result, the most potent derivative was found 6c. Furthermore, preliminary safety profile of most active compound 6c was evaluated by the neurotoxicity and acute oral toxicity testing.

Key words: Acute toxicity; Anticonvulsant; Neurotoxicity; Schiff’s bases






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.